Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Key Provisions

• House would declare that Food and Drug Administration policies for medication abortion care should follow transparent scientific review and consider how easy it is for patients to get care.
• House would affirm that Congress gave the Food and Drug Administration the power to regulate drugs based on science, free from political interference.
• House would state that the Food and Drug Administration has repeatedly found mifepristone safe and effective over 25 years, including when prescribed through telemedicine and dispensed by mail or at a pharmacy.
• House would emphasize that protecting and expanding access to medication abortion, including through telemedicine and mail/pharmacy, is important for fair access for many communities.